insights_auto
Sebab 500124 menurun 2.06%?
Terokai Dengan Lebih Terperincichevron_right
500124:BOM
Dr Reddy's Laboratories Ltd
₹1,214.10
arrow_downward
-2.06%(-25.55) 1H
14 Okt, 3:53:17 PTG GMT+5:30 · INR
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk 500124...
Buka
₹1,237.35
Tinggi
₹1,237.35
Rendah
₹1,209.65
Permodalan Pasaran
1.01T
Purata volum
85.80K
Volum
43.85K
Dividen
0.66%
Dividen suku tahunan
₹2.00
Tarikh tanpa dividen
10 Jul 2026
Nisbah H/P
31.40
tgi 52 mgu
₹1,414.40
rdh 52 mgu
₹1,080.05
EPS
₹38.67
Syer tertunggak
166.06J
Bilangan pekerja
28K
Buka
₹1,237.35
Tinggi
₹1,237.35
Rendah
₹1,209.65
Permodalan Pasaran
1.01T
Purata volum
85.80K
Volum
43.85K
Dividen
0.66%
Dividen suku tahunan
₹2.00
Tarikh tanpa dividen
10 Jul 2026
Nisbah H/P
31.40
tgi 52 mgu
₹1,414.40
rdh 52 mgu
₹1,080.05
EPS
₹38.67
Syer tertunggak
166.06J
Bilangan pekerja
28K
Cerita berita
Daripada sumber web dan rakan kongsi berita
TipRanks
·
9 jam lalu
Dr. Reddy’s Receives USFDA Form 483 After Pre-Approval Inspection at Visakhapatnam Plant
www.marketscreener.com
·
2 hari lalu
Dr. Reddy's Laboratories Shares Rise After BNP Paribas Upgrade
Profil
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Perihal Dr Reddy's Laboratories Ltd
CEOErez Israeli
Pekerja27.5K
Diasaskan1984
Ibu pejabatHyderabad, Andhra Pradesh, India
Sektor-
Laman webdrreddys.com